Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review
Human Reproduction2007Vol. 22(5), pp. 1200–1209
Citations Over TimeTop 10% of 2007 papers
Abstract
The limited RCT evidence to date does not show adverse metabolic risk with the use of the OCP compared with metformin. Further long-term RCTs are required.
Related Papers
- → The comparison of free androgen index and serum free testosterone levels in women with hirsutism or polycystic ovary syndrome(2011)5 cited
- → Prevalence of polycystic ovaries in women with acne(1989)42 cited
- → Hirsutism scoring in polycystic ovary syndrome: concordance between clinicians' and patients' self-scoring(2010)14 cited
- → Hirsutism and Acne(2011)1 cited